Stryker Will Sell CMR Surgical's Robot In The US As A Minority Investor, With A Plan To Buy The Company Later

CEO Kevin Lobo calls the CMR Surgical deal "a high risk kind of a deal" as Stryker cuts its 2026 outlook on its last call before he exits.

Share
Stryker Will Sell CMR Surgical's Robot In The US As A Minority Investor, With A Plan To Buy The Company Later

Stryker, the medical device maker, will sell CMR Surgical's Versius surgical robot in the US as an investor rather than an owner, CEO Kevin Lobo said on the company's third-quarter earnings call on Thursday. The plan, he said, is to buy CMR eventually.

A deliberately de-risked bet

Lobo, who is Chair and CEO and was on his last of 57 earnings calls in that role, said Stryker wants "to de-risk this" by having its own people run US commercialization without owning CMR. "Our hope and our plan is that we will eventually purchase this," he said, adding that he would not say when.

He was blunt about the exposure. "It's a high risk kind of a deal," Lobo said, because development is still ongoing, and "we don't want to put all our eggs in this basket." An outright purchase, he told a Truist analyst, would bring big ongoing development costs and financial pressure on the rest of the portfolio.

Investor Relations Vice President Nick Mead said the agreement makes Stryker the exclusive US sales agent for Versius, which has been used in more than 50,000 procedures globally. Lobo said the agreement has not closed yet but will "close shortly," and that Stryker will hold a board seat. "It's still their company," he said.

Aiming at laparoscopic and open surgery

Asked by a Wells Fargo analyst how Stryker would compete with the incumbent soft-tissue robot, Lobo said there is "plenty of room for two players." The biggest opportunity, he said, is converting laparoscopic and open surgery to robotic, not winning share from the rival. He pointed to high-volume procedures such as gallbladder removals, appendectomies and hernias, and to the robot's modular design for hospitals and ambulatory surgery centers.

Lobo said Versius is further along than Mako, the robotic-arm joint system Stryker bought, was when it acquired it. Unlike Mako, which sells with implants attached, he called this a pure adjacency.

A weak quarter and a lower outlook

The deal landed alongside a guidance cut. Chief Financial Officer Preston Wells said Stryker now expects full-year organic sales growth of 6.5% to 7% and adjusted earnings of $14.80 to $14.90 a share, citing softer hip and knee procedures and lingering supply constraints in peripheral vascular. Third-quarter organic sales rose 7.7% and adjusted earnings were $3.52 a share, up 10.3%.

Lobo said results fell short of expectations, blaming a slowdown in the hip and knee market, a first-quarter cyber incident and a July SAP software rollout in orthopaedics. Stryker repurchased $1 billion of shares in the quarter and received board authorization for another $3 billion. Spencer Stiles is the incoming CEO. Stryker's market value was $116.6 billion at Thursday's close.

Lobo told analysts that once Stryker eventually acquires CMR, it can speak more openly about its plans for the robot.

Sources

More on Stryker

All Stryker (SYK) coverage →